Clinical trials of bemcentinib (BGB324), a selective Axl tyrosine kinase inhibitor, have demonstrated promising activity in a range of Axl-expressing cancers, both as monotherapy and in combination with immune checkpoint inhibitors. This evidence concerns the gene AXL and cancer.